As they wait to hear from regulators on both sides of the Atlantic about their first-in-class severe asthma drug tezepelumab, Amgen, Inc. and AstraZeneca PLC have presented promising data on the effectiveness of the therapy in patients who also suffer from nasal polyps.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?